Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NuDYN
- Development stage
- Phase 4
- Lead developer
- Fidia Farmaceutici
- Administration
- Intraarticular, Intralesional
01
Overview
NuDYN is a shelf-stable, injectable, flowable amniotic membrane-derived allograft developed by Fidia Pharma USA Inc. for the treatment of musculoskeletal and orthopedic conditions. Derived from donated human placentas via cesarean delivery, the product is processed to be acellular while retaining intrinsic biological components such as hyaluronic acid, collagen, and various growth factors. It is regulated by the FDA as a human cell, tissue, and cellular and tissue-based product (HCT/P) under Section 361 of the Public Health Service Act. NuDYN is primarily utilized in non-surgical applications to support the health of cartilage, tendons, ligaments, and soft tissues, and is available by prescription in 1 mL and 2 mL vials.
- Brand names
- NuDYN
- Other names
- amniotic membrane-derived allograft
Beyond the preview
Go deeper on NuDYN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NuDYN.